Prognostic gene signature for normal karyotype AML
Patients with cytogenetically normal acute myeloid leukemia (CN-AML) show heterogeneous treatment outcomes. We used gene expression profiling to develop a gene signature that predicts overall survival (OS) in CN-AML. Based on data from 163 patients treated in the German AMLCG 1999 trial and analyzed on oligonucleotide microarrays, we used supervised principal component analysis to identify 86 probe sets (representing 66 different genes) which correlated with OS, and defined a prognostic score ba...
Provenance — who produced it, who reused it
Linked to 87 papers in the literature. Roles are inferred factual signals (who deposited the data vs who reused it), with counts — never a judgement about any author.
- Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like... 2015 · 2,558 cites
- Targeting the RNA m6A Reader YTHDF2 Selectively Compromises Canc... 2019 · 552 cites
- Notch pathway activation targets AML-initiating cell homeostasis... 2013 · 153 cites
- Induction of a Timed Metabolic Collapse to Overcome Cancer Chemo... 2020 · 132 cites
- The Long Noncoding RNA MALAT-1 is A Novel Biomarker in Various C... 2016 · 112 cites
75 further papers cite this accession but reuse could not be confirmed.
Deep data QC
metadata only · no data-level QC for this typeStandardized, field-standard QC computed by touching the data — every metric states how it was obtained
No quantitative QC rubric exists for this data type yet, so it is deliberately left unscored — this is an honest "not applicable", not a poor rating.
measured = computed from the data · extrapolated/reported = derived or from the repository · dq-1.0 · provisional — verify independently
Scientific quality
Based on hands-on reproduction of the papers that use this dataset. A reproducible paper that stands on this data is positive evidence; a flagged one is a prompt to look closer — never a verdict on the dataset itself without the evidence.